Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsJan 16 08:31 ET · Ratings

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Cuts Target Price to $22

Moomoo NewsJan 14 08:31 ET · Ratings

Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsJan 14 08:31 ET · Ratings

Express News | Astria Therapeutics Inc : Jefferies Raises Target Price to $29 From $27

ReutersJan 13 10:39 ET

Astria Therapeutics Announces ALPHA-ORBIT Phase 3 Trial Design For Navenibart In HAE; Features 3- And 6-Month Dosing, Primary Analysis At 6 Months; Expected Q1 2025 Initiation And Early 2027 Results; Strong Financial Position Supports Until Top-Line...

BenzingaJan 13 08:20 ET

Express News | Astria Therapeutics Inc: Alpha-Orbit Top-Line Results Anticipated in Early 2027.

ReutersJan 13 08:03 ET